Jason Citta, MD
Family Medicine · North Platte, NENPI 1538187893
Payments from drug & device makers
Across 403 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$809
- Amgen$577
- Johnson & Johnson$518
- Boehringer Ingelheim$408
- Novo Nordisk$385
- Pfizer$361
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,851100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 58 | $809 |
| Amgen | 43 | $577 |
| Johnson & Johnson | 34 | $518 |
| Boehringer Ingelheim | 31 | $408 |
| Novo Nordisk | 26 | $385 |
| Pfizer | 49 | $361 |
| AbbVie(2 entities) | 20 | $259 |
| Daiichi Sankyo Inc. | 14 | $249 |
| Exact Sciences | 16 | $240 |
| Astellas Pharma US Inc | 11 | $198 |
| AstraZeneca | 7 | $176 |
| Sanofi-aventis U.S. LLC | 11 | $175 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Eisai Inc. | 2 | $140 |
| Novartis | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 6 | $95 |
| Supernus Pharmaceuticals, Inc. | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 4 | $78 |
| Mylan Specialty L.p. | 6 | $77 |
| Merck | 5 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Organon | 3 | $71 |
| Dexcom, Inc. | 4 | $63 |
| Biowound Solutions, Inc. | 2 | $46 |
| GSK | 3 | $40 |
| Genentech USA, Inc. | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
| Soleno Therapeutics, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Philips North America LLC | 2 | $29 |
| Bayer | 2 | $29 |
| Abbott | 1 | $24 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$122
How this compares
$5,856 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $64,206 |
| JardianceEmpagliflozin | 108 | $54,501 |
| RybelsusSemaglutide | 35 | $34,346 |
| JanuviaSitagliptin Phosphate | 36 | $31,553 |
| XareltoRivaroxaban | 41 | $28,406 |
| TrulicityDulaglutide | 26 | $27,100 |
| OzempicSemaglutide | 20 | $18,860 |
| EntrestoSacubitril/Valsartan | 48 | $16,561 |
| MounjaroTirzepatide | 14 | $15,350 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $15,208 |
| MyrbetriqMirabegron | 31 | $14,413 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $13,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,686 |
| Repatha SureclickEvolocumab | 12 | $6,337 |
| Atorvastatin Calcium | 315 | $4,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $361 | $64,20695 claims |
| Boehringer IngelheimJardiance | $408 | $54,501108 claims |
| Novo NordiskRybelsus, Ozempic | $385 | $53,20555 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $809 | $42,45140 claims |
| MerckJanuvia | $75 | $31,55336 claims |
| Johnson & JohnsonXarelto | $518 | $28,40641 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $40 | $26,37052 claims |
| NovartisEntresto | $118 | $16,56148 claims |
| Astellas Pharma US IncMyrbetriq | $198 | $14,41331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in North Platte
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.